David A. Qualls

Oncology
450 Brookline Ave
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.

Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.

Journal: Blood advances
Published: August 20, 2025

Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.

Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.

Journal: Blood advances
Published: August 20, 2025

Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure.

Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure.

Journal: HemaSphere
Published: May 06, 2025

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia.

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia.

Journal: Blood advances
Published: January 24, 2025

Deep immunophenotypic dissection and clinical impact of T cells in the follicular lymphoma microenvironment.

Deep immunophenotypic dissection and clinical impact of T cells in the follicular lymphoma microenvironment.

Journal: Haematologica
Published: August 02, 2024

Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers.

Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers.

Journal: Haematologica
Published: June 06, 2024

The current landscape of frontline large B-cell lymphoma trials.

The current landscape of frontline large B-cell lymphoma trials.

Journal: Blood
Published: June 03, 2024

A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.

A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.

Journal: Blood advances
Published: March 14, 2024

A road map for navigating CAR T hematotoxicity.

A road map for navigating CAR T hematotoxicity.

Journal: Blood
Published: September 07, 2023

Comorbidities in DLBCL: too "Severe4" CAR-T therapy?

Comorbidities in DLBCL: too "Severe4" CAR-T therapy?

Journal: Blood advances
Published: July 14, 2023

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.

Journal: Blood
Published: June 08, 2023

Personalized approaches for treatment-naïve mantle cell lymphoma.

Personalized approaches for treatment-naïve mantle cell lymphoma.

Journal: Expert review of hematology
Published: February 07, 2023
Showing 1-12 of 28

Last Updated: 09/26/2026